Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06053242 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
A Phase 1 study of Chronic Low Back Pain and Degenerative Disc Disease, sponsored by Creative Medical Technology Holdings.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06053242: Recruiting Phase 1 study of Chronic Low Back Pain and Degenerative Disc Disease, sponsored by Creative Medical Technology Holdings.
NCT06053242 is a Phase 1 study of Chronic Low Back Pain and Degenerative Disc Disease that is actively recruiting participants, run by Creative Medical Technology Holdings. The registered enrollment target is 45 participants, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06053242, a Phase 1 study of Chronic Low Back Pain and Degenerative Disc Disease, is actively recruiting participants, sponsored by Creative Medical Technology Holdings.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.
Primary Outcome
The primary outcome will be evaluated by the incidence of grade 3 or 4 or serious adverse events in all dosing cohorts at 6 months.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CELZ-201-DDT
Study Locations (1)
Florida
- Spine and Wellness Centers of America - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 1 |
What NCT06053242 shows while recruiting
NCT06053242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Chronic Low Back Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06053242 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06053242 about?
NCT06053242 is a clinical study titled "Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain". The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.
What is the current status of trial NCT06053242?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2024-05-21. Estimated completion is 2027-05-01.
What conditions does trial NCT06053242 study?
This clinical trial studies the following conditions: Chronic Low Back Pain, Degenerative Disc Disease.
What interventions are being tested in trial NCT06053242?
The interventions under investigation include: Placebo (OTHER), CELZ-201-DDT (DRUG).
Who is sponsoring clinical trial NCT06053242?
This trial is sponsored by Creative Medical Technology Holdings, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06053242 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Low Back Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06053242's enrollment target sits among peer trials
45 48th of 71 higher than 24 of 71 other Chronic Low Back Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Low Back Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin Therapy for Chronic Low Back Pain
RECRUITING · Phase 1
-
Psilocybin in Chronic Low Back Pain and Depression
RECRUITING · Phase 1
-
Integrative Breathwork Intervention for Chronic Pain
RECRUITING · Phase 1
-
Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain
COMPLETED · Phase 1
-
Mobile Neurofeedback for Low Back Pain
RECRUITING · NA
-
Phenotyping Response to Spinal Cord Stimulation in Chronic Low Back Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI